Mounjaro®
Starting from £179.99/mo
Start journey Learn moreBoth Mounjaro (tirzepatide) and Wegovy (semaglutide) produce side effects that are predominantly gastrointestinal — nausea, loose stools, constipation, indigestion — and the evidence shows neither is dramatically kinder than the other. What matters more than which injection you choose is how carefully the dose is titrated, and whether a prescriber is supervising that process. These are prescription-only medicines; a clinician decides whether either is right for you. If you are weighing up how the two injections compare on tolerability, the honest answer is that individual response varies considerably, and the clinical trial data show both medicines are manageable for most people when started at the lowest dose and increased slowly.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common side effects of both Mounjaro and Wegovy are nausea, vomiting, diarrhoea, constipation, stomach discomfort, and fatigue. This is not a coincidence. Both medicines work through overlapping gut-hormone pathways that slow how quickly food moves through the stomach, and that mechanism is precisely what causes the GI symptoms. You can read the full patient-level breakdown on the NHS medicines page for tirzepatide and its equivalent for semaglutide.
Mounjaro adds a second hormone pathway (GIP alongside GLP-1) which is why it is sometimes described as producing stronger appetite suppression. Whether that dual action translates into more or fewer side effects depends on the person. Clinical trial data do not show a clear, consistent tolerability advantage for either medicine overall.
What the evidence does show is that timing matters. Side effects are most common in the first few weeks and after each dose increase. Starting at the lowest licensed dose (2.5mg for Mounjaro, 0.25mg for Wegovy) and moving up only when your body has had time to adjust is the standard approach for both. The pace of that titration is set by your prescriber, not by you. That is one of the core reasons these medicines require a prescription and ongoing clinical supervision rather than a one-off purchase.
If you want a broader picture of the side effects of weight loss injections across both medicines in more detail, that page covers the full picture.
The question of which weight loss injection has the least side effects is partly the wrong question to ask first. A more useful frame is: what affects how well anyone tolerates either medicine? Several things are within the prescriber's control, and a few are within yours.
Dose titration speed is the single biggest lever. Both medicines have licensed schedules that build up gradually over months precisely because rapid dose increases generate far more nausea and GI disruption than a slower climb. Skipping steps or rushing (which sometimes happens without adequate clinical oversight) is a reliable way to make side effects worse.
Diet choices during treatment also make a difference. High-fat meals, large portions, and alcohol tend to amplify nausea. Eating smaller amounts more slowly, staying well hydrated, and keeping protein intake reasonable all help. This is not a guarantee (some people feel nauseated regardless) but it is practical and evidence-consistent.
Individual biology plays a role too. Some people sail through the first pen with minimal symptoms; others find the first few weeks genuinely uncomfortable. There is no reliable way to predict which camp you will fall into before starting. A prescriber who knows your medical history and any relevant conditions is better placed than an algorithm to make that call. Our weight loss injections overview page explains how both options work in more detail if you are still at the research stage.
Most GI side effects from weight loss injections are unpleasant but not dangerous. They are worth noting, worth mentioning at your next review, and worth reporting if they are severe. A few symptoms, though, require prompt action rather than waiting to see if they settle.
Seek medical help the same day (or call 999 if severe) if you experience any of the following:
Severe stomach pain that spreads towards your back, with or without vomiting. This may indicate pancreatitis, which the MHRA flagged in a January 2026 Drug Safety Update as an infrequent but serious risk with GLP-1 medicines. Do not treat this as ordinary nausea.
Signs of serious dehydration from vomiting or diarrhoea, dizziness on standing, very dark urine, being unable to keep fluids down. Dehydration can affect kidney function and needs proper assessment.
Symptoms of a possible allergic reaction, swelling of the face, lips or throat, difficulty breathing, or a spreading rash.
Gallbladder symptoms, sharp pain in the upper right abdomen, especially after eating, sometimes with fever or yellowing of the skin.
Low mood, thoughts of self-harm, or significant mood changes, tell your prescriber and, if urgent, contact NHS 111 or emergency services.
The Yellow Card scheme allows patients to report any suspected side effects directly to the MHRA, it is one of the ways regulators monitor these medicines in real-world use, and your report genuinely contributes to that picture.
Our prescribers go through side-effect risks and what to watch for as a standard part of the consultation. You can find more about the side effects of weight loss injections ahead of any conversation with them.
If you are comparing options and want to understand which weight loss injections come with the least side effects, that is a reasonable starting point, but choosing between Mounjaro and Wegovy on the basis of side-effect tolerance alone is rarely straightforward, because the evidence does not reliably point one way for the general population. A prescriber working through your case will factor in your medical history, any conditions that raise or lower the risk of specific side effects, other medicines you take, and your own preferences about injection frequency and dose format.
Transfer patients coming from one medicine sometimes switch partly for tolerability reasons. That is a legitimate clinical conversation, not something to self-manage by ordering a different pen from a different site. If you are already on treatment and finding it hard going, speaking to your prescriber before stopping is important, abrupt discontinuation is not the only option.
nume does not work here: at our pharmacy, a GPhC-registered prescriber reads your answers personally. There is no triage bot between you and the clinical decision. The consultation is also the natural place to raise any concerns before your first pen arrives, rather than discovering you have questions after the fact, perhaps on a Tuesday evening when the pen is already in the fridge door next to the milk. Our clinical lead's background is set out on the clinical team page. When you are ready, checking your eligibility is free and takes a few minutes.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.